Edward Esplin
Clinical Geneticist
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (27)
Year:
2026
Year:
2025
Indications for and implications of germline genetic testing (GGT) in patients with prostate cancer have expanded over the past decade, particularly related to precision therapies and management. GGT has become the standard of care for many cancers such as breast, ovarian, colorectal, pancreatic, and metastatic prostate cancer, and it is imperative that patients be offered timely and equitable access to testing as it can inform patient-physician shared decision making for management of the current cancer as well as anticipatory guidance for disease progression. Additionally, GGT guides screening for and prevention of secondary malignancies for the patient and cascade testing for at-risk family members. Here, we present data supporting the notion that clinicians should offer all patients with prostate cancer the opportunity to undergo comprehensive GGT for pathogenic germline variants known to be associated with familial cancer and/or known to have implications for treatment and management.
Year:
2025
Year:
2025
Year:
2025
PURPOSE The prevalence of pathogenic/likely pathogenic germline variants (PGVs) in gastric cancer (GC) predisposition genes is not well understood. We aimed to determine this in patients with GC undergoing germline genetic testing at a large commercial laboratory. METHODS This was a cross-sectional study. Retrospective review of genetic testing in patients with GC at a commercial laboratory (Invitae Corp) from March 2015 to July 2023 was performed. Prevalence of PGVs was determined and compared with a control cohort of 20,139 individuals unaffected by cancer. Data were abstracted from test requisition forms. RESULTS In total, 3,706 patients with GC underwent genetic testing, of which 494 (13.3%) patients carried PGVs, 1,200 (32.4%) had variants of uncertain significance, and 1,890 (51%) had negative testing. PGVs were identified in 38 genes, of which 385 of 494 (77.9%) were in a gene previously associated with GC, including 35% in homologous recombination repair genes ( BRCA1 , BRCA2 , PALB2 , and ATM ), 19.5% in Hereditary Diffuse GC genes ( CDH1 and CTNNA1 ), and 17.4% in Lynch syndrome genes ( MLH1 , MSH2 , MSH6 , PMS2 , and EPCAM ). Comparing the GC cohort with the unaffected cohort, it was found that there was significant enrichment of PGVs in most GC-associated genes, except for APC , EPCAM , MUTYH , and PMS2 . Odds of carrying a PGV was increased significantly in males and patients with a personal history of another cancer with odds ratio (OR) of 1.3 (95% CI, 1.1 to 1.6) and OR, 1.4 (95% CI, 1.1 to 1.7), respectively. CONCLUSION In this large study of genetic testing in patients with GC, more than one in eight patients referred for germline testing was found to harbor a PGV in a cancer predisposition gene, which is higher than previous estimates. Most PGVs were identified in genes previously associated with GC.
Year:
2025
Background: The presence of variants of uncertain significance (VUS) should not influence clinical management; however, prior studies on breast cancer–related health care utilization in women with VUS versus negative germline genetic test results have shown conflicting findings. This study evaluated whether receipt of a VUS influences breast cancer–related health care utilization. Methods: This large study analyzed health care utilization and costs in women who underwent clinical multigene panel testing (MGPT) between 2015 and 2023 at a single commercial laboratory with ≥2 years of health insurance claims data available. Multivariable logistic regression was used to assess differences in the uptake of surgical, therapeutic, risk-reducing, and surveillance modalities, as well as the associated health care costs, between women with VUS or negative MGPT results after the return of test findings. Results: Of 50,657 eligible women (mean age, 47.7 years), most were White (66.8%), had a family history of cancer (87.0%), and had commercial insurance (71.1%). Among 22,699 patients with breast cancer, those with VUS showed no differences from those with negative results in the uptake of surgical, therapeutic, risk-reducing, and surveillance procedures or in the adjusted cost of surgical procedures after genetic testing. Among 27,958 cancer-free women, those with negative results had modestly lower mammography use (odds ratio, 0.9; 95% CI, 0.8–0.9) compared with those with VUS. Breast cancer screening and treatment costs were no higher for women with VUS versus negative results, but were up to 10 times higher for those with positive results. Conclusions: In a large, real-world sample of women with breast cancer and without any cancer, use of cancer treatments, surveillance, and risk-reducing measures did not differ between patients with VUS versus negative results, except for modestly higher mammography use. These findings offer reassurance that VUS results do not lead to overutilization or increased cost of health care.
Year:
2025
Sarcomas are rare heterogenous mesenchymal tumors with over seventy-five different subtypes, with varying biology and outcomes, with no clear inciting factor in the vast majority. To determine the prevalence of pathogenic germline variants (PGV) in patients with sarcomas, we undertook a prospective multi-site study of germline sequencing using an 84-gene next-generation sequencing panel among patients receiving care at the four Mayo Clinic Cancer Centers. Of 115 patients with bone and soft tissue sarcoma, the median age was 60 years, 49.6% were female, 82.6% were White. The anatomical location of the primary tumor included extremities (34.8%), retroperitoneum (19.1%), trunk (13.0%), and head and neck (7.8%). Family history of cancer was present in 62.6% of the study population. Ten patients (8.7%) had a pathogenic/likely pathogenic variant (PGV). Of these, three had stage IV sarcoma, and seven had earlier-stage sarcoma (stages I–III). Among the 55 (48.7%) patients who had variant of uncertain significance (VUS), 41.1% (22/55) had stage IV sarcoma and 58.9% (33/55) had earlier-stage disease. Of the ten patients with PGV, high-to-moderate penetrance gene abnormalities were identified in eight patients (80%) involving TP53 (3), BRCA1 (1), SDHA (1), ATM (2), and NBN (1) genes. The vast majority of the PGVs (70%) would not have been detected using the current guidelines. Because of the paucity of sarcomas and lack of effective treatment options for advanced disease, germline testing in sarcomas represents a potentially impactful strategy to assess therapeutic options and for assessment of familial risk.
Year:
2025
Year:
2025
Supplementary Fig. S1: Analysis of FH variants and their associated interpretations of pathogenicity. Supplementary Fig. S2: Kinetic parameters for active/partially-active VUS/CI. Supplementary Fig. S3: Recombinant FH produced for 74 VUS/CI. Supplementary Fig. S4: Michaelis-Menten graphs for VUS/CI incubated with fumarate. Supplementary Fig. S5: Michaelis-Menten graphs for VUS/CI incubated with malate. Supplementary Fig. S6: Broad analysis of recombinant FH. Supplementary Fig. S7: Multimerization status of 74 VUS/CI. Supplementary Fig. S8: Tetramerization correlates with catalytic activity. Supplementary Fig. S9: Expression of FH variants in HLRCC cells. Supplementary Fig. S10: Fumarate accumulation decreases TCA intermediates. Supplementary Fig. S11: FH loss enhances de novo glutathione biosynthesis. Supplementary Fig. S12: Coessentiality of FH and nucleotide biosynthesis genes. Supplementary Fig. S13: Loss of FH activity disrupts de novo purine biosynthesis. Supplementary Fig. S14: Dysregulated purine metabolism is independent of HLRCC cell proliferation rate. Supplementary Fig. S15: FH-deficient cells use the purine salvage pathway to maintain purine nucleotide levels. Supplementary Fig. S16: Pyrimidine metabolism in FH-deficient and FH-expressing cells. Supplementary Fig. S17: Disrupting expression of purine salvage enzymes impairs tumor growth. Supplementary Fig. S18: Purine salvage inhibitor 6-mercaptopurine (6-MP) impairs tumor growth.
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (23)
Pedro Barata
Associate Professor of Medicine
University Hospitals Seidman Cancer Center
Blake Wilde
Assistant Professor
Roswell Park Comprehensive Cancer Center
Stacy Gray
Associate Clinical Professor
City of Hope
Stephanie Hernandez
University of California, Los Angeles
James Ford
Professor
Stanford University
Yusra Shao
Assistant Professor
Karmanos Cancer Institute
Maha Hussain
Professor
Northwestern University
Alan Haruo Bryce
Chief Clinical Officer
City of Hope
Gail Tomlinson
Professor
The University of Texas Health Science Center at Houston
Brian Shuch
University of California
Aziz Khan
Assistant Professor
Mohamed Bin Zayed University of Artificial Intelligence
Christina Curtis
Professor of Medicine & Genetics
Stanford University
Emmanuel Stylianos Antonarakis
Professor of Medicine, Associate Director for Translation
-
Rebecca Previs
Duke University
Michael Snyder
Chairman and Professor
Stanford University School of Medicine
Heather Christofk
Professor
David Geffen School of Medicine at UCLA
Hayan Lee
Assistant Professor
Fox Chase Cancer Center
William Greenleaf
Professor
Stanford University
Rachel E. Ellsworth
-
Yizhou Zhu
Yeshiva University
Kevin Hughes
Director of Cancer Genetics McKoy Rose Professor of Surgery
Medical University of South Carolina
Emma Monte
University of California, Los Angeles
Anshul Kundaje
Associate Professor
Stanford University
Make your next move.
Prepare your application
Review drafts before you send them.